

Supplementary Table 1. Demographic and clinical features of the cutoff selection and validation cohorts from the EPOCA study

	Oligoarthritis		p	Polyarthritis		p
	Selection 979	Validation 1859		Selection 957	Validation 2155	
Males, n (%)	263 (26.9)	523 (28.1)	0.500	219 (22.9)	527 (24.5)	0.364
Age at disease onset, yrs.	3.7 [2.0, 7.4]	3.8 [2.1, 7.5]	0.278	4.1 [2.0, 8.4]	5.0 [2.2, 8.9]	0.013
Disease duration, yrs.	3.1 [1.5, 6.0]	3.2 [1.3, 6.4]	0.977	5.3 [2.7, 8.8]	4.6 [2.3, 7.9]	0.001
Geographic area, n (%)			<0.00 1			<0.00 1
Africa & Middle East	176 (18.0)	207 (11.1)		40 (4.2)	305 (14.2)	
Eastern Europe	296 (30.2)	337 (18.1)		327 (34.2)	427 (19.8)	
Latin America	41 (4.2)	166 (8.9)		74 (7.7)	197 (9.1)	
North America	36 (3.7)	98 (5.3)		98 (10.2)	118 (5.5)	
Northern Europe	44 (4.5)	158 (8.5)		132 (13.8)	229 (10.6)	
Southeast Asia	0 (0.0)	32 (1.7)		0 (0.0)	57 (2.6)	
Southern Europe	307 (31.4)	711 (38.2)		233 (24.3)	589 (27.3)	
Western Europe	79 (8.1)	150 (8.1)		53 (5.5)	233 (10.8)	
JADAS10	2.4 [0.0, 7.0]	2.5 [0.1, 6.5]	0.800	3.5 [0.5, 8.5]	4.4 [1.0, 10.5]	0,037
cJADAS10	2.0 [0.0, 6.0]	2.0 [0.0, 6.0]	0.556	3.5 [0.5, 8.5]	4.0 [0.5, 10.0]	0,067
Subjective rating of disease activity			0.056			0.115
ID, n (%)	510 (52.1)	1062 (57.7)		461 (48.2)	954 (45.3)	
Minimal disease activity, n (%)	264 (27.0)	417 (22.7)		254 (26.6)	561 (26.6)	
Moderate disease activity, n (%)	183 (18.7)	332 (18.0)		206 (21.5)	477 (22.6)	
High disease activity, n (%)	22 (2.2)	29 (1.6)		35 (3.7)	115 (5.5)	